Large clinician survey reveals key prescribing trends for chemotherapy-induced anemia in 2015.
By Amy Brenner, Epidemiologist
18 April 2016
I joined Datamonitor Healthcare as an Epidemiologist in 2015 after completing an MSc in Epidemiology from the London Sch...
Read full bio
In order to investigate prescribing habits and treatment choices for chemotherapy-induced anemia (CIA), Datamonitor Healthcare conducted a survey of 259 hematologists and nephrologists in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Pharmacological treatment options include erythropoiesis-stimulating agents (ESA) and intravenous iron, while non-pharmacological treatments such as red blood cell transfusions and oral iron supplements are also used. Treatment choices vary by severity of CIA, with moderate CIA representing the largest market for pharmacological treatment. Interestingly, the survey revealed that a substantial proportion of patients with moderate CIA in Japan go untreated, representing a potentially important target market. The ESA Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) as a monotherapy is the most commonly used pharmacological treatment; however, the range of ESAs prescribed differs by country due to variation in the degree of competition from biosimilars as well as marketing capabilities. Treatment contraindications related to major safety concerns create an unmet need for alternative therapies, as demonstrated by a mean score of 6.7 out of 10 for physicians’ overall satisfaction with current treatment options.
Proportion of chemotherapy-induced anemia patients receiving each type of ESA, alone or as part of a combination, by country, 2015
Source: Datamonitor Healthcare
Datamonitor Healthcare’s Chemotherapy-induced Anemia: Treatment provides a detailed analysis of diagnosis rates, patient segmentations, and current treatment patterns and prescribing trends, as well as an overview of unmet needs in CIA.
Get your free demo today – simply fill in the form to the right.